Trade In Your SkinPen Precision®, RejuvaPen NXT®, Exceed®, Or Eclipse EVO® And Upgrade To SkinStylus® With Up To A $1,500 Trade-In Value!
You will never speak to a sales rep. In fact, SkinStylus® costs 40% less than other options because we cut out all sales reps and middlemen and replaced them with clinicians. Book your call now and speak with Kristin Groop, 21-year clinician and co-inventor of the SkinStylus MicroSystem®.
|FDA cleared to 2.5 mm|
|12 pin, 36 pin, and 36 pin HiLo technology|
|Three different FDA cleared cartridge configurations for maximum flexibility|
|Can either be intermediate disinfected or autoclave reprocessed without need for sheath|
|FDA cleared with both battery (cordless) and corded power options|
|FDA cleared with a THREE YEAR Warranty|
|Patented Seven-Step Safety System that prevents cross-contamination|
|Cartridges utilize gamma ray sterilization|
The SkinStylus SteriLock® MicroSystem is the only system cleared by the FDA to be used on all six skin types.
Unlike laser, IPL, and chemical peels, SkinStylus® MicroSystems can be used on all skin types without the fear of hypopigmentation, hyperpigmention, burning, and most importantly, recent mild-to-moderate sun exposure.
SkinStylus® is “a masterpiece of American ingenuity”, with Class II clearance and clinical data on file with FDA.gov.
12 pin, 36 pin, and 36 pin HiLo technology is not available in any other system.
SkinStylus® includes a Three Year Warranty depending on the selected package.
Both corded and cordless options are available.
Trade in sealed, unexpired cartridges, 1-for-1 for SteriLock® cartridges.
Removable nosecones can be reprocessed in an autoclave or disinfected with CaviCide®.
14 hours of research-supported video education available upon purchase of your new SkinStylus®.
Schedule a call with a 21-year clinician now.
Never speak to a sales rep.
The SkinStylus SteriLock® MicroSystem has been cleared by the FDA as a Class II Medical Device for the indication of treating abdominal scars (such as tummy tuck scars) to 2.5 mm, in adults over 22 years old. In a controlled clinical trial, 2 out of 3 physician graders observed a clinically meaningful improvement in 22 out of 30 subjects (73%). Clinical data on file.